» Articles » PMID: 38347769

Prevalence and Predictors of Diabetic Peripheral Neuropathy in Newly Diagnosed Type 2 Diabetes Mellitus Patients

Overview
Specialty Endocrinology
Date 2024 Feb 13
PMID 38347769
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: The present study aimed to determine the prevalence and predictors of DPN in newly diagnosed T2DM patients.

Background: Diabetic Peripheral Neuropathy (DPN) is the most common and debilitating complication of Type 2 Diabetes Mellitus (T2DM).

Methods: Newly diagnosed T2DM patients visiting the outpatient department were recruited. Detailed demographic parameters, histories, physical examinations, and biochemical investigations were carried out. Patients were screened for DPN using the Diabetic Neuropathy Symptom (DNS) score, the revised Disability Neuropathy Score (NDS), Vibration Perception Threshold (VPT) using a biosthesiometer, and the 10 g SW Monofilament Test (MFT).

Results: A total of 350 newly diagnosed T2DM patients (mean age 46.4±13.6 years) were included. The prevalence of DPN was found to be 34% using the combined DNS and NDS scores. VPT was moderately impaired in 18.3% and severely impaired in 12% patients, while MFT revealed a loss of protective sensation in 35.4% patients. After logistic regression analysis, DPN was significantly associated with increasing age (OR 1.08, 95%CI 1.06-1.11), increasing HbA1C levels (OR 1.23, 95%CI 1.05-1.42), increasing TSH levels (OR 1.23, 95%CI 1.05-1.44), presence of hypertension (OR 2.78, 95%CI 1.51-5.11), and reduced BMI (OR 0.9, 95%CI 0.84- 0.99). The sensitivity and specificity of detecting DPN by combining VPT and MFT were 91.6% and 84.2%, respectively.

Conclusion: The prevalence of DPN was high even in newly diagnosed T2DM and associated significantly with increasing age, HbA1C levels, TSH levels, hypertension, and reduced BMI. Earlier screening for DPN, along with aggressive control of glycemia, blood pressure, and hypothyroidism, may be beneficial.

Citing Articles

IL-20RA is Associated with the Risk of Diabetic Microangiopathy: A Bidirectional Mendelian Randomization Analysis and Clinical Validation.

Li J, Yang H, Wang T, Ruan N, Lin Y, Fang Z Diabetes Metab Syndr Obes. 2024; 17:4803-4816.

PMID: 39712242 PMC: 11663374. DOI: 10.2147/DMSO.S480366.


Causal relationship between hypothyroidism and peripheral neuropathy: a Mendelian randomization study of European ancestry.

Duan X, Zhang T, Wang K Front Endocrinol (Lausanne). 2024; 15:1436823.

PMID: 39665022 PMC: 11631618. DOI: 10.3389/fendo.2024.1436823.


Comprehensing the role of serum GGT in colorectal carcinoma: cancer risk, prognostic and diagnostic significance.

Anupam S, Goel S, Mehta D, Das R Clin Transl Oncol. 2024; .

PMID: 39565548 DOI: 10.1007/s12094-024-03791-z.


Diabetic peripheral neuropathy and neuromodulation techniques: a systematic review of progress and prospects.

Mittal R, McKenna K, Keith G, McKenna E, Lemos J, Mittal J Neural Regen Res. 2024; 20(8):2218-2230.

PMID: 39359078 PMC: 11759018. DOI: 10.4103/NRR.NRR-D-24-00270.

References
1.
Pradeepa R, Mohan V . Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr. 2017; 71(7):816-824. DOI: 10.1038/ejcn.2017.40. View

2.
Mathur P, Leburu S, Kulothungan V . Prevalence, Awareness, Treatment and Control of Diabetes in India From the Countrywide National NCD Monitoring Survey. Front Public Health. 2022; 10:748157. PMC: 8964146. DOI: 10.3389/fpubh.2022.748157. View

3.
Pop-Busui R, Boulton A, Feldman E, Bril V, Freeman R, Malik R . Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2016; 40(1):136-154. PMC: 6977405. DOI: 10.2337/dc16-2042. View

4.
Tesfaye S, Boulton A, Dyck P, Freeman R, Horowitz M, Kempler P . Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010; 33(10):2285-93. PMC: 2945176. DOI: 10.2337/dc10-1303. View

5.
Ang L, Jaiswal M, Martin C, Pop-Busui R . Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014; 14(9):528. PMC: 5084623. DOI: 10.1007/s11892-014-0528-7. View